Antileukotriene agents

Current Opinion in Pulmonary Medicine

Volumn 3, Issue 3, 1997, Pages 215-220

  Tan, Ricardo Antonio ^a   Spector, Sheldon L ^a  

^a Allergy Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; DRUG DERIVATIVE; HYDROXYUREA; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; TOLUENESULFONIC ACID DERIVATIVE; ZAFIRLUKAST; ZILEUTON;

ASTHMA; HUMAN; PHYSIOLOGY; REVIEW;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; HYDROXYUREA; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; LIPOXYGENASE INHIBITORS; TOSYL COMPOUNDS;

EID: 0031136894     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199705000-00006     Document Type: Article

References (46)

1. Holgate ST, Bradding P, Sampson AP: Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996, 98:1-13. A comprehensive review of leukotrienes and the studies done with the various types of antileukotrienes.
2. National Asthma Education and Prevention Program: Guidelines for the Diagnosis and Management of asthma. Bethesda: National Institutes of Health; 1997. The latest recommendations from the NIH, which include zafirlukast and zileuton in the treatment guidelines.
3. Kellaway CH, Trethewie ER: The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol 1940, 30:121-145.
4. Spector SL: Leukotriene inhibitors and antagonists in asthma. Ann Allergy Asthma Immunol 1995, 75:463-474. This article in a good review of the antileukotriene agents and the rationale for their usefulness in clinical practice.
5. Henderson WR Jr: Eicosanoids and lung inflammation. Am Rev Respir Dis 1987, 135:1176-1185.
6. Buckner CK, Krell RO, Laravuso RB, Coursin DB, Bernstein PR, Will JA: Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4. J Pharmacol Exp Ther 1986, 237:558-662.
7. Busse WW: The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy 1996, 26:868-879. An in-depth analysis of the physiology of the leukotrienes and their involvement in allergic diseases.
8. Labat C, Ortiz JL, Norel X: A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther 1992, 263:800-805.
9. Hay DW: Pharmacology of leukotriene receptor antagonists. Chest 1997, 111(suppl):35S-45S. This article is an excellent review of the basic research into the physiology of leukotrienes.
10. Drazen JM: Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic subjects. Ann N Y Acad Sci 1988, 524:289-297.
11. 4 [abstract]. Am Rev Respir Dis 1985, 131:A24.
12. 4 on the airways responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 1988, 82:654-660.
13. 4 and platelet-activating factor on airway reactivity in normal subjects. Am Rev Respir Dis 1990, 141:993-997.
14. 4 on glycoprotein and lysosome secretion by human bronchial mucosa. Prostaglandins 1983, 25:155-170.
15. Kaliner MA: Basic mechanisms in asthma: an emerging and personal view. J Respir Dis 1987, 135:S6-S9.
16. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993, 341:989-990.
17. 4-induced potentiation of human airway smooth muscle proliferation [abstract]. Am J Respir Crit Care Med 1996, 153:A842.
18. Ellis JL, Undem BJ: Role of peptidoleukotrienes in capsaicin-sensitive sensory fibre-mediated responses in guinea-pig airways. J Physiol (Lond) 1991, 436:469-484.
19. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1990, 141:988-992.
20. 4 receptor antagonism in the airways of asthmatics [abstract]. Am J Respir Crit Care Med 1994, 149:A465.
21. Meltzer SS, Cohn J, Bleech ER, Hasday JD: Inhibition of exercise-induced asthma by zileuton, a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996, 153:931-935.
22. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993, 147:1413-1418.
23. Taylor IK, O'Shaughnessy KM, Fuller RW, Dolery CT: Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airways hyperreactivity in atopic subjects. Lancet 1991, 337:690-694.
24. 4 antagonist, MK-571 [abstract]. Ann N Y Acad Sci 1991, 629:436.
25. Grossman J, Faiferman I, Tompson DJ, Busse W, Bronsky E, Montanaro A, Southern L, Tinkelman D: Results of the first U.S. double-blind, placebo-controlled multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma 1997, in press.
26. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993, 147:1431-1435.
27. O'Byrne PM, Watson RM, Strong HA, Wylie G: The effect of treatment with a 5-lipoxygenase inhibitor, BAYx1005 on allergen-induced asthmatic responses in human subjects [abstract]. Am J Respir Crit Care Med 1994, 149:A532.
28. 4 receptor antagonist, ICI 204,219, on cold air-induced bronchoconstriction in patients with asthma [abstract]. J Allergy Clin Immunol 1994, 93:295.
29. Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, Drazen JM: The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990, 323:1740-1744.
30. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, Cohn J, Rubin P, Drazen JM: Tha pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993, 148:1447-1451.
31. Yamamoto H, Nagata M, Kuramitsu K, Tabe K, Kiuchi H, Sakamoto Y, Yamamoto K, Dohi Y: Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994, 150:254-257.
32. Fijimura M, Sakahoto S, Kamis Y, Matsuda T: Effect of a leukotriene antagonist ONO 1078 on bronchial hyperresponsiveness in patients with asthma. Respir Med 1993, 87:133-138.
33. Spector S, Miller CJ, Glass M: Thirteen-week dose-response study with Accolate (zafirlukast) in patients with mild-to-moderate asthma [abstract]. Am J Respir Crit Care Med 1995, 151:A379.
34. Hui KP, Barnes NC: Lung function improvement in asthma with a cysteinyl leukotriene receptor antagonist. Lancet 1991, 337:1062-1063.
35. Lockey RF, Lavins BJ, Snader L: Effects of 13 weeks of treatment with ICI 204,219 (Accolate) in patients with mild-to-moderate asthma [abstract]. J Allergy Clin Immunol 1995, 95:350.
36. Spector SL, Smith LJ, Glass M: Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994, 150:618-623.
37. Barnes NC, de Jong B, Miyamoto T: Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Chest 1997, 111(suppl):52S-60S.
38. Liu M, Dube LM, Lancaster J, Zileuton Study Group: Acute and chronic effects of a 5-lipoxygenass inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996, 98:859-871.
39. Israel E, Cohn J, Dube L, Drazen J, Zileuton Study Group: Chronic 5-lipoxygenase inhibition by zileuton significantly decreases the requirement for acute steroid treatment of asthma [abstract]. Am J Respir Crit Care Med 1995, 151:A678.
40. Virchow JC, Noller PS, Wiessman KJ: Multicenter trial of BAY x1005, a new 5-lipoxygenase-activating protein inhibitor in the treatment of chronic asthma [abstract]. Am J Respir Crit Care Med 1995, 151:A377.
41. Nathan RA, Glass M, Snader L: Effects of 13 weeks of treatment with ICI 204,219 (Accolate) or cromolyn sodium (intal) in patients with mild and moderate asthma [abstract]. J Allergy Clin Immunol 1995, 95:388.
42. Schwartz HJ, Petty T, Reed R, Dube LM, Swanson LJ, Zileuton Study Group: The comparative affects of zileuton, a 5-lipoxygenase inhibitor, vs. Theophylline in patients with moderate asthma: results from a 13-week, multicenter trial [abstract]. Am J Respir Crit Care Med 1995, 151:A376.
43. McGill KA, Busse WW: Zileuton. Lancet 1996, 348:519-524. A review of the relevant research on zileuton.
44. Spector SL: Management of asthma with zafirlukast clinical experience and tolerability profile. Drugs 1996, 52(suppl 6):36-46. This article covers all the important studies on the efficacy and safety of zafirlukast.
45. 4-receptor antagonist, ICI:204,219, relieves symptoms of acute seasonal silergic rhinitis. Am J Respir Crit Care Med 1995, 151:1734-1739.
46. Knapp HR: Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990, 323:1745-1748.